Your browser doesn't support javascript.
loading
Identification of triazinoindol-benzimidazolones as nanomolar inhibitors of the Mycobacterium tuberculosis enzyme TDP-6-deoxy-d-xylo-4-hexopyranosid-4-ulose 3,5-epimerase (RmlC).
Sivendran, Sharmila; Jones, Victoria; Sun, Dianqing; Wang, Yi; Grzegorzewicz, Anna E; Scherman, Michael S; Napper, Andrew D; McCammon, J Andrew; Lee, Richard E; Diamond, Scott L; McNeil, Michael.
Affiliation
  • Sivendran S; Penn Center for Molecular Discovery, Department of Chemical and Biomolecular Engineering, Institute for Medicine and Engineering, 1024 Vagelos Research Laboratories, University of Pennsylvania, Philadelphia, PA 19104, USA.
Bioorg Med Chem ; 18(2): 896-908, 2010 Jan 15.
Article in En | MEDLINE | ID: mdl-19969466
ABSTRACT
High-throughput screening of 201,368 compounds revealed that 1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one (SID 7975595) inhibited RmlC a TB cell wall biosynthetic enzyme. SID 7975595 acts as a competitive inhibitor of the enzyme's substrate and inhibits RmlC as a fast-on rate, fully reversible inhibitor. An analog of SID 7975595 had a K(i) of 62nM. Computer modeling showed that the binding of the tethered two-ringed system into the active site occurred at the thymidine binding region for one ring system and the sugar region for the other ring system.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Benzimidazoles / Carbohydrate Epimerases / Enzyme Inhibitors / Indoles / Mycobacterium tuberculosis Type of study: Diagnostic_studies Limits: Humans Language: En Year: 2010 Type: Article

Full text: 1 Database: MEDLINE Main subject: Benzimidazoles / Carbohydrate Epimerases / Enzyme Inhibitors / Indoles / Mycobacterium tuberculosis Type of study: Diagnostic_studies Limits: Humans Language: En Year: 2010 Type: Article